Krystal Biotech (NASDAQ:KRYS) Earns “Overweight” Rating from Cantor Fitzgerald

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research note issued on Thursday,Benzinga reports. They currently have a $215.00 price objective on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 14.45% from the company’s previous close.

KRYS has been the topic of several other reports. Chardan Capital raised their price objective on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday. Citigroup raised their price objective on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, HC Wainwright restated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research note on Wednesday. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $210.00.

Krystal Biotech Stock Up 2.9 %

Shares of KRYS opened at $187.86 on Thursday. The business’s fifty day moving average is $157.37 and its 200 day moving average is $175.23. Krystal Biotech has a 12-month low of $107.50 and a 12-month high of $219.34. The stock has a market cap of $5.40 billion, a P/E ratio of 62.83 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. During the same period last year, the business earned $0.30 EPS. The business’s revenue was up 116.4% on a year-over-year basis. On average, analysts expect that Krystal Biotech will post 6.14 EPS for the current year.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 14.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Several large investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new stake in Krystal Biotech in the 4th quarter worth about $95,000. Palisades Investment Partners LLC increased its holdings in Krystal Biotech by 9.3% in the 4th quarter. Palisades Investment Partners LLC now owns 40,479 shares of the company’s stock worth $6,341,000 after acquiring an additional 3,436 shares during the last quarter. Woodline Partners LP increased its holdings in Krystal Biotech by 23.0% in the 4th quarter. Woodline Partners LP now owns 221,102 shares of the company’s stock worth $34,638,000 after acquiring an additional 41,287 shares during the last quarter. Soleus Capital Management L.P. increased its holdings in Krystal Biotech by 65.2% in the 4th quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock worth $56,144,000 after acquiring an additional 141,400 shares during the last quarter. Finally, ProShare Advisors LLC increased its holdings in Krystal Biotech by 28.6% in the 4th quarter. ProShare Advisors LLC now owns 8,848 shares of the company’s stock worth $1,386,000 after acquiring an additional 1,967 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).